Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Toxicol Appl Pharmacol. 2010 Apr 25;246(1-2):8–17. doi: 10.1016/j.taap.2010.04.015

Figure 8.

Figure 8

A. Hepatic iNOS mRNA expression was measured by real time PCR in mice at 6 h and 12 h after 600 mg/kg APAP treatment. Data are expressed as the iNOS-to-actin mRNA ratio; the value of untreated control animals was set as 1. Some of the animals received 15 ml/kg PBS, 15 ml/kg DMSO/PBS or 10 mg/kg SP600125 in DMSO/PBS at 1 h before APAP administration. Data represent means ± SE of n = 3 animals per group. *P<0.05 (compared to C), #P<0.05 (compared to APAP/PBS). B. Western blot analysis of iNOS expression in livers of controls or animals treated with 600 mg/kg APAP for 6 h. One to three representative samples are shown from each group. The numbers under the blot show the results of the densitometric analysis. Data of control animals were set as 1. C. Plasma nitrate plus nitrite, which were used as a marker of NO production, and D. plasma ALT activities were measured at 6 h after 600 mg/kg APAP or 2 mg/kg endotoxin (ET). Some of the animals received 15 ml/kg PBS (P), 15 ml/kg DMSO (8.3% in PBS) (D) or 10 mg/kg SP600125 in DMSO/PBS (SP) at 1 h before APAP administration. An additional group was treated with 3.3 mg/kg of the iNOS inhibitor L-N-(1-iminoethyl)lysine (NIL) at 0 and 3 h after APAP or LPS administration. Data represent means ± SE of n= 3-4 animals per group. *P<0.05 (compared to C), #P<0.05 (compared to P).